{"name":"UniQure Biopharma B.V.","slug":"uniqure-biopharma-b-v","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"AMT-191","genericName":"AMT-191","slug":"amt-191","indication":"Other","status":"phase_1"},{"name":"AMT-162","genericName":"AMT-162","slug":"amt-162","indication":"Other","status":"phase_1"},{"name":"Glybera","genericName":"ALIPOGENE TIPARVOVEC","slug":"alipogene-tiparvovec","indication":"Familial lipoprotein lipase deficiency","status":"marketed"}]}],"pipeline":[{"name":"AMT-191","genericName":"AMT-191","slug":"amt-191","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AMT-162","genericName":"AMT-162","slug":"amt-162","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glybera","genericName":"ALIPOGENE TIPARVOVEC","slug":"alipogene-tiparvovec","phase":"marketed","mechanism":"Gene therapy","indications":["Familial lipoprotein lipase deficiency"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQTXByczRZNnY0dGpfVlZWNkVLNndxdm5JREYxWTJuSEp1Z0RCTnlXLWFrT09tOVplNmNLQjktMHZxaVFIVTBYMDc3UlhWd19vQXgzNUNuYVZXTy1ncDRBUUxyUXpZZnFQcjdvWnNobVJ1ODdLaW9NMWxwc1F3MHZGTWNyY1k0UzdiaEFGVndtWm5kZw?oc=5","date":"2026-03-03","type":"regulatory","source":"statnews.com","summary":"FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says - statnews.com","headline":"FDA is ‘not convinced’ UniQure’s Huntington’s therapy has benefit, senior official says","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-03","type":"pipeline","source":"PR Newswire","summary":"Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Th","headline":"Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxOZFZUbi1sYzFyNXdnZlFUS2xzTjFEamFrUEt5RXh3S1RwcFhlaHNvajdfWlItR2lMZTZlR2JkNm5zQlpyNTRSbmFlQ0VhTWxBQkFsOU9CODRCZ2Z2TG0tMTBLNEJ3cG9FNTNBeC1YRjdUMW9lZkZVMTk4TGFDVXRvbw?oc=5","date":"2025-11-03","type":"regulatory","source":"statnews.com","summary":"UniQure’s FDA submission for its Huntington’s disease therapy thrown into question - statnews.com","headline":"UniQure’s FDA submission for its Huntington’s disease therapy thrown into question","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOZWNMUElzQzhfVXlVcEIycTk5ZTFXcFZoMkRZUHEwemVCRXB3YXBWRF80Q1VOOUhXcnQ3c0s0bE44Um5DVmtUaHcxTWpUVFJPYWNncTZ6NE5oU294V0hYWnZqMUt6N2hsS1dTQ09kSmhCYUZfVkN6SzdtM3ZRUWNPNXUzSEk2THAtc0dUWUI0MV9mWC12Z2tHTng2anYyc2NoRzJHVQ?oc=5","date":"2024-11-12","type":"pipeline","source":"Fierce Biotech","summary":"Bayer drops Huntington's gene therapy to focus on 'most promising assets' - Fierce Biotech","headline":"Bayer drops Huntington's gene therapy to focus on 'most promising assets'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQSWJ1OTJCSTZTY1ZkR2dFYTl2a3EyTWZWREpjeTBySUIwbzI1UmlRU2VaOGtvN2hTZmRSSEpUd29lVjhLa3JTZEhHTUgtZU9xcWY5S0tnTUlnWmx3RmV6M0hVcmN3SHg2X1k2VmdVTlBVTHFEZVE3UHZpSkV6UFZielotLVNnM3N0b1pHYUMwb0FMRFRxNU9xNGt3UGxESS1fdnc?oc=5","date":"2024-10-20","type":"pipeline","source":"seekingalpha.com","summary":"uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring - seekingalpha.com","headline":"uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQei1ad05va01MTmE2T0lHeXA5MDNiTWt1UmZJcnViZHBncmQ2SE5IOUhYQ2pmT3VmdFEzdG9YSkg2dWc4SkJIc0RVd0s4ZWF5V0VxaVpKc0o0R1BSY1BuNXoxSzQzdExfd2x6VVZlNEtQX1VHVzloT2l6eEkzUWE4bm9nQ2pHclNPVkVoVmJxTGR4VE9fWF9PUXo4OGxqb3JjUjEtRjdHS2RSMGMtMno0QU9OWXk0XzZhbG9iRWxYOGZ6eVZkX0JLdFNZZ2Q?oc=5","date":"2023-06-20","type":"pipeline","source":"McCarthy Tétrault LLP","summary":"Federal Court rejects stay in Pfizer Canada ULC and Pfizer Inc. v. uniQure Biopharma B.V. - McCarthy Tétrault LLP","headline":"Federal Court rejects stay in Pfizer Canada ULC and Pfizer Inc. v. uniQure Biopharma B.V. - McCarthy Tétrault LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOY2JOSXF0eWRRaTB0bExCcUlPTVd0X1ZZX0RTMDhRWDctUWEwNExkN1VEeU1GWk92S0Y1X0ZYLWp5R3VLcEtRT1BkU0w2VlU1d0NmNUFxd1hrb0xweDdqa0w5WmVBY3ItQWh1cUNIMENVVHhiQ05mTWRyN1pkal8ybUlPQ0JiQ1Y4QmNGVlpDdnZUNWhRZWNJS0dRR1NSZ01KaTB2azN5eF9pU2F3WG1McHhaZGhJdWxzVW5fMUxhdUFEZmprSGtlSlRIY3psREdCY0NTU2dDeEhQMEg1X0Fpd0FMbzBDZlFhbXZoTkhzSmtpZy1mUXRFYmNqZEM?oc=5","date":"2021-05-21","type":"patent","source":"IPWatchdog.com","summary":"Patent Filings Roundup: New NPE Solid-State Drive Suit Against Micron, Western Digital; Redfin Indemnitee Files IPR on Virtual Reality Tour Patents - IPWatchdog.com","headline":"Patent Filings Roundup: New NPE Solid-State Drive Suit Against Micron, Western Digital; Redfin Indemnitee Files IPR on V","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOLTJ2ck41d09MVnpYcDNaeElEYWV0TjdJay0zYzFBbFhsTEtJQ3ZvVDNHUGM5bXd3Q1NuclV4b3BuS0xZbGVXRFdob1c0M3ZiOUlxajF3RjQ4bjhaVXNuaHhzU1o3dTE5emNiUE5Bb2NnQkFpYkM4SDdEa0IzNEhiV081YjlzNm5qRllSZkdlOXl5bFFWbm5PNkpKWUI?oc=5","date":"2017-04-21","type":"pipeline","source":"European Biotechnology Magazine","summary":"Uniqure withdraws €1m drug Glybera from market - European Biotechnology Magazine","headline":"Uniqure withdraws €1m drug Glybera from market","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"marketed":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}